Alnylam Pharmaceuticals
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Domain
alnylam.com
Country
United StatesIndustry
BiotechnologyEmployees
1001-5000
Last Funding
$661.3M
Founded
2001
Tech Stack (19 technologies)
Frequently Asked Questions
What technologies does Alnylam Pharmaceuticals use?+
Alnylam Pharmaceuticals uses 19 technologies including Bootstrap, Drupal, Google Tag Manager.
What industry is Alnylam Pharmaceuticals in?+
Alnylam Pharmaceuticals operates in the Biotechnology industry.
Where is Alnylam Pharmaceuticals based?+
Alnylam Pharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026